Irbesartan Generis Phar

Irbesartan, the active ingredient in Irbesartan Generis Phar, is a Angiotensin II receptor blocker (ARB) presented as an oral dosage form for oral use. It is used to manage hypertension and to slow the progression of diabetic nephropathy in adult patients.

GNH USA supplies Irbesartan Generis Phar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from comprehensive technical support and timely delivery across multiple continents.

Irbesartan is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

Hypertension: reduces systolic and diastolic blood pressure, helping to lower cardiovascular risk. Diabetic nephropathy: slows decline of renal function and reduces proteinuria in patients with type 2 diabetes. Chronic kidney disease associated with hypertension: contributes to renal protection and stabilises kidney function.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue or mild weakness. - Nausea or abdominal discomfort. - Elevated serum potassium.

Serious or Rare Side Effects: - Angioedema involving face, lips, tongue or airway. - Acute kidney injury or worsening renal function. - Severe hyperkalemia leading to cardiac arrhythmia. - Hepatic injury with jaundice. - Significant hypotension causing syncope.

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly to assess therapeutic response. - Assess renal function and serum creatinine at baseline and periodically. - Check serum potassium levels, especially if combined with potassium‑sparing agents. - Use with caution in patients with hepatic impairment. - Avoid in individuals with known hypersensitivity to irbesartan or other ARBs. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients. - Dual therapy with another ARB or ACE inhibitor. - Potassium‑sparing diuretics or supplements (risk of hyperkalemia). - Lithium (increased lithium levels and toxicity). - Strong CYP2C9 inhibitors (e.g., fluconazole) that may raise irbesartan concentrations.

Moderate Interactions (Monitor Closely): - Loop or thiazide diuretics (enhanced hypotensive effect). - NSAIDs (potential reduction in antihypertensive efficacy and renal function). - Other antihypertensives (additive blood‑pressure lowering). - Rifampin (may decrease irbesartan plasma levels).